INS and type 1 diabetes mellitus: Type 1 diabetes (T1D), a condition marked by the autoimmune destruction of the insulin-producing pancreatic β-islet cells, is estimated to affect 9 million people globally and involves life-long insulin replacement therapy, complex dietary planning and places patients at an elevated risk of developing co-morbidities, altogether signifying a high disease burden for this population (1, 2).